255823-06-4

Basic information

• Product Name: 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)-
• Synonyms: 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)-;(3R,4R)-3-Amino-4-(hydroxymethyl)-1-pyrrolidinecarboxylic acid phenylmethyl ester;(3S,4S)-benzyl 3-aMino-4-(hydroxyMethyl)pyrrolidine-1-carboxylate (S)-2-hydroxy-2-phenylacetate
• CAS NO: 255823-06-4
• Molecular Formula: C13H18N2O3
• Molecular Weight: 250.296
• Mol File: 255823-06-4.mol

Chemical Properties

• Boiling Point: 414.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.225
• PKA: 14.93±0.10(Predicted)
• CAS DataBase Reference: 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)-(255823-06-4)
• EPA Substance Registry System: 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)-(255823-06-4)

Safety Data

• Hazardous Substances Data: 255823-06-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)is used as a research compound for exploring its potential in drug discovery and development. Its specific stereoisomeric configuration may contribute to unique biochemical and pharmaceutical properties, making it a valuable molecule for further investigation in the field of medicinal chemistry.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 1-PYRROLIDINECARBOXYLIC ACID, 3-AMINO-4-(HYDROXYMETHYL)-, PHENYLMETHYL ESTER, (3R,4R)is utilized as a starting material or intermediate in the synthesis of new pharmaceutical agents. Its structural features and stereochemistry can be leveraged to design and develop innovative drugs with improved efficacy and selectivity.

Upstream product

• 497-19-8 sodium carbonate 
• 7440-66-6 zinc 
• 370880-76-5 benzyl N-[2-(hydroxyimino)ethyl]-N-(prop-2-en-1-yl)carbamate 
• 1463484-39-0 benzyl 3,3a,4,6-tetrahydropyrrolo[3,4-c]isoxazole-5-carboxylate 
• 501-53-1 benzyl chloroformate 
• 114790-39-5 benzyl N-(2,2-dimethoxyethyl)carbamate 
• 569682-60-6 benzyl N-(2,2-dimethoxyethyl)-N-(prop-2-en-1-yl)carbamate 
• 370880-75-4 benzyl N-(2-oxoethyl)-N-(prop-2-en-1-yl)carbamate 
• 252770-09-5 (±) benzyl 3-amino-4-(hydroxymethyl)pyrrolidine-1-carboxylate 

Downstream Products

• 246510-70-3 benzyl (3S,4S)-3-tert-butoxycarbonylamino-4-methylsulfonyloxymethyl-pyrrolidine-1-carboxylate 
• 799279-84-8 (1R,5S)-3-benzyl 6-tert-butyl 3,6-diazabicyclo[3.2.0]heptane-3,6-dicarboxylate 
• 799279-83-7 benzyl (3S,4S)-3-(amino)-4-{[(methylsulfonyl)oxy]methyl}-1-pyrrolidinecarboxylate trifluoroacetate 

Relevant articles and documents

OXALAMIDO-SUBSTITUTED TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS

The present invention relates to compounds that are inhibitors of hepatitis B virus (HBV). Compounds of this invention are useful alone or in combination with other agents for treating, ameliorating, preventing or curing HBV infection and related conditions. The present invention also relates to pharmaceutical compositions containing said compounds.

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Certain disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane are described, which are useful as orexin inhibitors. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS

Disubstituted 3,8-diaza-bicyclo[4.2.0]octane and 3,6-diazabicyclo [3.2.0]heptane compounds are described, which are useful as orexin receptor modulators. Such compounds may be useful in pharmaceutical compositions and methods for the treatment of diseased states, disorders, and conditions mediated by orexin activity, such as insomnia.

Synthesis and structure-activity relationship studies of 3,6-diazabicyclo[3.2.0]heptanes as novel α4β2 nicotinic acetylcholine receptor selective agonists

A series of novel, potent neuronal nicotinic acetylcholine receptor (nAChR) ligands derived from 3,6-diazabicyclo[3.2.0]heptane have been synthesized and evaluated for binding affinity and agonist activity at the α4β2 nAChR subtype. Structure-activity relationship studies of these novel nAChR ligands focused on substitution effects on the pyridine ring, as well as stereo- and regiochemical influences of the 3,6-diazabicyclo[3.2.0]heptane core. Small 5-substituents on the pyridine ring had a modest impact on the binding affinities and functional activities. 6-Bromo, 6-chloro, and 6-methyl substituents on the pyridine ring led to increased binding affinities and improved functional activities. Most of the 6-N-pyridinyl-substituted 3,6-diazabicyclo[3.2.0]heptanes are selective for the α4β2 nAChR subtype. Compounds (1R,5S)-25, (1R,5S)-55, and (1R,5S)-56 were virtually inactive as agonists at the hα3β4 nAChR but retained potency and efficacy at the hα4β2 nAChR subtype. 3-N-Pyridinyl-substituted series demonstrated more complex SAR. (1R,5R)-39, (1R,5R)-41, and (1R,5R)-42 were found to be much more potent at the hα3β4 nAChR subtype, whereas (1R,5R)-38 and (1R,5R)-40 were very selective at the hα4β2 nAChR subtype. The SAR studies of these novel ligands led to the discovery of several compounds with interesting in vitro pharmacological profiles.

(1S,5S)-3-(5,6-dichloropyridin-3-YL)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate

The present invention relates to the salt (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate and to methods of preparing the salt.

Amino-substituted tricyclic derivatives and methods of use

Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives.

Amino-substituted tricyclic derivatives and methods of use

Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y1 and Y2 form various tricyclic cores, Xa and Xb are C, CH, or N, as defined herein, and Rx is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives. Methods of using amino-substituted tricyclic derivatives also are described herein.

Substituted diazabicycloalkane derivatives

Compounds of formula (I) [in-line-formulae]Z-Ar1—Ar2??(I) [/in-line-formulae] wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

Substituted diazabicycloakane derivatives

Compounds of formula (I) Z-Ar1—Ar2??(I) wherein Z is a diazabicyclic amine, Ar1 is a 5- or 6-membered aromatic ring, and Ar2 is selected from an unsubstituted or substituted 5-membered heteroaryl ring; an unsubstituted or substituted 6-membered heteroaryl ring; 3,4-(methylenedioxy)phenyl; and phenyl substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.